GlassScriptPhysician profile
Gilbert J Toffol
NPI 1760470967
$31,851.51
in general payments reported to CMS, 2019-2025
74 companies · $267 in 2025
The $267 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,805 · 2020: $3,952 · 2021: $6,028 · 2022: $6,314 · 2023: $5,832 · 2024: $3,653 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,552 · Consulting Fee: $150 · Education: $50.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,551.78 |
| Consulting Fee | $150.00 |
| Education | $50.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $3,268.06 | 2019-2024 | Vumerity, Tysabri |
| Abbvie INC. | $2,988.78 | 2019-2024 | Botox, Qulipta, Duopa |
| Novartis Pharmaceuticals Corporation | $2,662.35 | 2019-2024 | |
| Ucb, INC. | $2,118.34 | 2019-2024 | Briviact, Nayzilam, Rystiggo |
| Emd Serono, INC. | $1,825.90 | 2019-2024 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $1,341.00 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
| Acadia Pharmaceuticals INC | $1,319.30 | 2019-2024 | Nuplazid |
| Lilly USA, LLC | $1,247.65 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Pfizer INC. | $958.65 | 2020-2025 | |
| Allergan, INC. | $868.69 | 2019-2022 | |
| Genzyme Corporation | $824.54 | 2019-2023 | |
| Horizon Therapeutics Plc | $713.57 | 2021-2023 | Uplizna |
| Celgene Corporation | $613.80 | 2020-2024 | Zeposia |
| Mdd US Operations, LLC | $605.29 | 2019-2022 | |
| Amgen INC. | $559.17 | 2019-2024 | Uplizna |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilbert Toffol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.